Current Problems in Cancer
Volume 32, Issue 3 , Pages 143-154 , May 2008

Proteomics: The New Frontier Also for Brain Tumor Research

  • Vaibhav Chumbalkar, MD

      Affiliations

    • Department of Neurosurgery, Brain Tumor Center, University of Texas MD Anderson Cancer Center, Houston, Texas
    • ,
  • Raymond Sawaya, MD

      Affiliations

    • Anne C. Brooks and Anthony D. Bullock, Distinguished Chair in Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas
    • Chair of Neurosurgery, Baylor College of Medicine, Houston, Texas
    • ,
  • Oliver Bogler, PhD

      Affiliations

    • Associate Professor, Brain Tumor Center and Departments of Neurosurgery and Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas

References 

  1. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics. 2004;3:960–969
  2. Nie L, Wu G, Zhang W. Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. Biochem Biophys Res Commun. 2006;339:603–610
  3. Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4:1920–1932
  4. Uhlén M, Pontén F. Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics. 2005;4:384–393
  5. Pelech S. Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. Curr Pharm Biotechnol. 2004;5:69–77
  6. Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 2005;65:7674–7681
  7. Godovac-Zimmermann J, Brown LR. Perspectives for mass spectrometry and functional proteomics. Mass Spectrom Rev. 2001;20(1):1–57
  8. Pandey A, Mann M. Proteomics to study genes and genomes. Nature. 2000;405:837–846
  9. Sanchez JC, Rouge V, Pisteur M, Ravier F, Tonella L, Moosmayer M, et al. Improved and simplified in-gel sample application using reswelling of dry immobilized pH gradients. Electrophoresis. 1997;18:324–327
  10. Hanash SM, Bobek MP, Rickman DS, Williams T, Rouillard JM, Kuick R, et al. Integrating cancer genomics and proteomics in the post-genome era. Proteomics. 2002;2:69–75
  11. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B, et al. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res. 2005;4:698–708
  12. Okamoto H, Li J, Gläsker S, Vortmeyer AO, Jaffe H, Robison RA, et al. Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biol Ther. 2007;6:391–396
  13. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN, et al. Differential protein expression in human gliomas and molecular insights. Proteomics. 2005;5:1167–1177
  14. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN, et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene. 2004;23:6806–6814
  15. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res. 2004;64:2496–2501
  16. Senger DL, Tudan C, Guiot MC, Mazzoni IE, et al. Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. Cancer Res. 2002;62(7):2131–2140
  17. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A. 1994;91:7727–7731
  18. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996;56:5079–5086
  19. Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia. 2003;42:194–208
  20. Vogel TW, Zhuang Z, Li J, Okamoto H, Furuta M, Lee YS, et al. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res. 2005;11:3624–3632
  21. Puchades M, Nilsson CL, Emmett MR, Aldape KD, Ji Y, Lang FF, et al. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J Proteome Res. 2007;6:869–875
  22. Trog D, Fountoulakis M, Friedlein A, Golubnitschaja O. Is current therapy of malignant gliomas beneficial for patients? (Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions). Proteomics. 2006;6:2924–2930
  23. Lubman DM, Kachman MT, Wang H, Gong S, Yan F, Hamler RL, et al. Two-dimensional liquid separations-mass mapping of proteins from human cancer cell lysates. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;782:183–196
  24. Hamler RL, Zhu K, Buchanan NS, Kreunin P, Kachman MT, Miller FR, et al. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics. 2004;4:562–577
  25. Billecke C, Malik I, Movsisyan A, Sulghani S, Sharif A, Mikkelsen T, et al. Analysis of glioma cell platinum response by metacomparison of two-dimensional chromatographic proteome profiles. Mol Cell Proteomics. 2006;5:35–42
  26. Sheng S, Chen D, Van Eyk JE. Multidimensional liquid chromatography separation of intact proteins by chromatographic focusing and reversed phase of the human serum proteome: optimization and protein database. Mol Cell Proteomics. 2006;5:26–34
  27. Wang Y, Rudnick PA, Evans EL, Li J, Zhuang Z, Devoe DL, et al. Proteome analysis of microdissected tumor tissue using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-tandem MS. Anal Chem. 2005;77:6549–6556
  28. Guo T, Wang W, Rudnick PA, Song T, Li J, Zhuang Z, et al. Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem. 2007;55:763–772
  29. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A. 2007;104:12867–12872

PII: S0147-0272(08)00015-9

doi: 10.1016/j.currproblcancer.2008.02.005

Current Problems in Cancer
Volume 32, Issue 3 , Pages 143-154 , May 2008

Article Tools